{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:36:01Z","timestamp":1792103761793,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.08.022","type":"journal-article","created":{"date-parts":[[2017,11,5]],"date-time":"2017-11-05T18:02:19Z","timestamp":1509904939000},"page":"334-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":250,"special_numbering":"C","title":["Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial"],"prefix":"10.1016","volume":"86","author":[{"given":"N.","family":"Basset-S\u00e9guin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kunstfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dimier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fittipaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Xynos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.08.022_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","article-title":"Advanced basal cell carcinoma: epidemiology and therapeutic innovations","volume":"3","author":"Mohan","year":"2014","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.ejca.2017.08.022_bib2","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.022_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bjc.2014.270","article-title":"Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective","volume":"111","author":"Lear","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.08.022_bib4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/fon.14.281","article-title":"Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus","volume":"11","author":"Peris","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2017.08.022_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrc2503","article-title":"Basal cell carcinomas: attack of the hedgehog","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2017.08.022_bib6","series-title":"Vismodegib. Approved drugs","author":"US Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.ejca.2017.08.022_bib7","series-title":"Erivedge. European public assessment report","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.ejca.2017.08.022_bib8","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.08.022_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2017.08.022_bib10","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC Study","volume":"32","author":"Sekulic","year":"2014","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.022_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.ejca.2017.08.022_bib12","article-title":"Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study","volume":"33","author":"Yoo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.08.022_bib13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejca.2013.12.013","article-title":"Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease","volume":"50","author":"McCusker","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.08.022_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2017.08.022_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2017.08.022_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2017.08.022_bib17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.136.12.1524","article-title":"Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis","volume":"136","author":"Marcil","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2017.08.022_bib18","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","article-title":"Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis","volume":"49","author":"Flohil","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.08.022_bib19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/bjd.13630","article-title":"Persistent alopecia induced by vismodegib","volume":"172","author":"Alkeraye","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.08.022_bib20","series-title":"Erivedge (vismodegib) [prescribing information]","year":"2015"},{"key":"10.1016\/j.ejca.2017.08.022_bib21","series-title":"Erivedge (vismodegib) [summary of product characteristics]","year":"2016"},{"key":"10.1016\/j.ejca.2017.08.022_bib22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.08.022_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/fon-2016-0296","article-title":"Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma","volume":"13","author":"Fife","year":"2017","journal-title":"Future Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917312479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T20:10:26Z","timestamp":1668715826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917312479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"alternative-id":["S0959804917312479"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}